181 related articles for article (PubMed ID: 25656737)
1. Sunitinib tissue distribution changes after coadministration with ketoconazole in mice.
Chee EL; Lim AY; Modamio P; Fernandez-Lastra C; Segarra I
Eur J Drug Metab Pharmacokinet; 2016 Jun; 41(3):309-19. PubMed ID: 25656737
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib-ibuprofen drug interaction affects the pharmacokinetics and tissue distribution of sunitinib to brain, liver, and kidney in male and female mice differently.
Lau CL; Chan ST; Selvaratanam M; Khoo HW; Lim AY; Modamio P; Mariño EL; Segarra I
Fundam Clin Pharmacol; 2015 Aug; 29(4):404-16. PubMed ID: 26011058
[TBL] [Abstract][Full Text] [Related]
3. Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice.
Tan SY; Kan E; Lim WY; Chay G; Law JH; Soo GW; Bukhari NI; Segarra I
J Pharm Pharmacol; 2011 Jul; 63(7):918-25. PubMed ID: 21635257
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib-paracetamol sex-divergent pharmacokinetics and tissue distribution drug-drug interaction in mice.
Liew MH; Ng S; Chew CC; Koo TW; Chee YL; Chee EL; Modamio P; Fernández C; Mariño EL; Segarra I
Invest New Drugs; 2017 Apr; 35(2):145-157. PubMed ID: 28070719
[TBL] [Abstract][Full Text] [Related]
5. Diclofenac sex-divergent drug-drug interaction with Sunitinib: pharmacokinetics and tissue distribution in male and female mice.
Chew CC; Ng S; Chee YL; Koo TW; Liew MH; Chee EL; Modamio P; Fernández C; Mariño EL; Segarra I
Invest New Drugs; 2017 Aug; 35(4):399-411. PubMed ID: 28285369
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
Soo GW; Law JH; Kan E; Tan SY; Lim WY; Chay G; Bukhari NI; Segarra I
Anticancer Drugs; 2010 Aug; 21(7):695-703. PubMed ID: 20629201
[TBL] [Abstract][Full Text] [Related]
7. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans.
Speed B; Bu HZ; Pool WF; Peng GW; Wu EY; Patyna S; Bello C; Kang P
Drug Metab Dispos; 2012 Mar; 40(3):539-55. PubMed ID: 22180047
[TBL] [Abstract][Full Text] [Related]
9. Potential protective effect of sunitinib after administration of diclofenac: biochemical and histopathological drug-drug interaction assessment in a mouse model.
Tan JR; Chakravarthi S; Judson JP; Haleagrahara N; Segarra I
Naunyn Schmiedebergs Arch Pharmacol; 2013 Jul; 386(7):619-33. PubMed ID: 23552887
[TBL] [Abstract][Full Text] [Related]
10. Histopathology and biochemistry analysis of the interaction between sunitinib and paracetamol in mice.
Lim AY; Segarra I; Chakravarthi S; Akram S; Judson JP
BMC Pharmacol; 2010 Oct; 10():14. PubMed ID: 20950441
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model.
Szałek E; Karbownik A; Grabowski T; Sobańska K; Wolc A; Grześkowiak E
Pharmacol Rep; 2013; 65(5):1383-90. PubMed ID: 24399735
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib DDI with paracetamol, diclofenac, mefenamic acid and ibuprofen shows sex-divergent effects on the tissue uptake and distribution pattern of sunitinib in mice.
Tan SY; Wong MM; Tiew AL; Choo YW; Lim SH; Ooi IH; Modamio P; Fernández C; Mariño EL; Segarra I
Cancer Chemother Pharmacol; 2016 Oct; 78(4):709-18. PubMed ID: 27495788
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulations.
Yang Z; Vakkalagadda B; Shen G; Ahlers CM; Has T; Christopher LJ; Kurland JF; Roongta V; Masson E; Zhang S
J Clin Pharmacol; 2013 Feb; 53(2):217-27. PubMed ID: 23436267
[TBL] [Abstract][Full Text] [Related]
14. The influence of the time-of-day administration of the drug on the pharmacokinetics of sunitinib in rabbits.
Szałek E; Karbownik A; Sobańska K; Połom W; Grabowski T; Wolc A; Matuszewski M; Grześkowiak E
Eur Rev Med Pharmacol Sci; 2014 Aug; 18(16):2393-9. PubMed ID: 25219843
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
[TBL] [Abstract][Full Text] [Related]
16. The influence of the time-of-day administration of sunitinib on the penetration through the blood-brain and blood-aqueous humour barriers in rabbits.
Sobańska K; Karbownik A; Szałek E; Płotek W; Grabowski T; Szewczyk A; Marcinkowska D; Połom W; Matuszewski M; Grześkowiak E
Eur Rev Med Pharmacol Sci; 2016; 20(1):166-73. PubMed ID: 26813470
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib in combination with clarithromycin or azithromycin - is there a risk of interaction or not?
Szałek E; Karbownik A; Połom W; Matuszewski M; Sobańska K; Urjasz H; Grabowski T; Wolc A; Grześkowiak E
Pharmacol Rep; 2012; 64(6):1554-9. PubMed ID: 23406766
[TBL] [Abstract][Full Text] [Related]
18. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients.
Houk BE; Bello CL; Kang D; Amantea M
Clin Cancer Res; 2009 Apr; 15(7):2497-506. PubMed ID: 19258444
[TBL] [Abstract][Full Text] [Related]
19. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.
Hu S; Chen Z; Franke R; Orwick S; Zhao M; Rudek MA; Sparreboom A; Baker SD
Clin Cancer Res; 2009 Oct; 15(19):6062-9. PubMed ID: 19773380
[TBL] [Abstract][Full Text] [Related]
20. Effect of P-glycoprotein and breast cancer resistance protein inhibition on the pharmacokinetics of sunitinib in rats.
Kunimatsu S; Mizuno T; Fukudo M; Katsura T
Drug Metab Dispos; 2013 Aug; 41(8):1592-7. PubMed ID: 23749551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
